"10.1371_journal.pone.0072155","plos one","2013-08-28T00:00:00Z","Benjamin Vandendriessche; Elke Rogge; Vera Goossens; Peter Vandenabeele; Johannes-Peter Stasch; Peter Brouckaert; Anje Cauwels","Department for Molecular Biomedical Research, VIB, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium; Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany","Conceived and designed the experiments: BV PB AC. Performed the experiments: BV ER VG AC. Analyzed the data: BV VG AC. Contributed reagents/materials/analysis tools: PV JPS. Wrote the paper: BV AC.","Johannes-Peter Stasch is currently a full-time employee by Bayer Pharma AG. JPS holds more than 60 patent applications related to sGC stimulators, such as BAY 41-2272, and sGC activators, such as BAY 58-2667. Details of which are available on request. Bayer Pharma has not funded the research, nor have they had a role in study design, data collection or analysis. BAY 41-2272 and BAY 58-2667 were provided by Bayer Pharma AG (Germany) for this study, and are Bayer products. The sGC stimulator riociguat (BAY 63-2521) is currently in clinical development. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","08","Benjamin Vandendriessche","BV",7,TRUE,3,4,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
